INTRODUCTION

Epidermolysis bullosa (EB) is a group of inherited skin conditions characterized by the loss of skin integrity that leads to blisters and erosions with little or no trauma.

More than 20 genes associated with dermal–epidermal junction assembly are involved in this disease. As the phenotype highly variable, EB was originally classified into four major types (simplex, junctional, dystrophic, and Kindlersyndrome) and further subclassified in...
multiple clinical subtypes based on the level of blister formation in the cutaneous basement membrane zone and the underlying molecular etiology (Fine et al., 2014; Uitto, Bruckner-Tuderman, McGrath, Riedl, & Robinson, 2018). In addition, recent perspective proposes that EB may be classified in nonsyndromic and syndromic forms according to with or without extracutaneous clinical manifestations (Vahidnezhad, Youssefian, Saeidian, & Uitto, 2019). Recessive dystrophic epidermolysis bullosa (RDEB) is one of the most severe nonsyndromic forms, which is caused by biallelic loss-of-function variants in the collagen type VII gene (COL7A1, OMIM accession number: 120,120) (Wagner et al., 2010). In the present study, we identified two previously unreported recessive pathogenic variants of COL7A1 in an RDEB patient by using clinical exome sequencing (CES) and minigene assay.

2 | SUBJECTS AND METHODS

2.1 | Editorial policies and ethical considerations

This work was permitted by the ethics committee of Southwest Hospital, Third Military Medical University. The informed consent was obtained from patient for molecular study and publication.

2.2 | Clinical report

The patient was a 3-year-old Chinese Han girl who was the first child of an unrelated healthy couple. As birth certificate recording, the patient was born with weight 3.1 kg (25–50th percentile), height 48 cm (25–50th percentile), and head circumference 34 cm (50th percentile). The weight was 11 kg (3rd percentile), height 87 cm (3rd percentile), and head circumference 48 cm (25–50th percentile) at her 3 years. Her parents reported that she was noted skin absence of the lower left limb at birth, and had been suffering from slight trauma-induced blisters, blood blisters, scarring, and milia formation on the trunk, extremities, and neck since birth. Physical examination at the clinic shows that the skin lesion was particularly severe on her hands, feet, elbows, tibialis, and knees. She also had slightly webbed toes (but fingers unaffected), and dystrophic nails. Tooth decay and dental loss, and oral mucosal blood blisters were also detected (Figure 1a). Frequent melena and hematochezia were reported by the parents indicating that gastrointestinal mucosa injury was involved. The patient had normal facial feature, intelligence, speech, and vision, and no skeletal abnormality was observed. Abdominal and cardiac ultrasound assessment was not carried out due to the refusal of the parents. Skin biopsies were not performed for the same reason. The parents are healthy as neither of them had any signs indicating EB, including blistering, scarring, or nail dystrophy.
The parents had been told by a dermatologist that the patient might be involved in dystrophic epidermolysis bullosa (DEB), although no genetic testing was performed. Because the patient's mother had been pregnant for 8 weeks at the first visit, both of proband's gene diagnosis and prenatal diagnosis were expected to be provided.

### 2.3 Genetic analyses

We performed CES for the proband. Library preparation, in-solution hybridization exome capture, next-generation sequencing, and data analyses were conducted as previously described (Wang et al., 2019). Candidate causative variants identified in the proband were confirmed by Sanger sequencing. Parents were also tested to evaluate the mode of inheritance.

### 2.4 Minigene assay

The target genomic fragment of COL7A1 (GenBank, NG_007065.1, NM_000094.3) encompassing exons 62–66 was amplified by PCR using the proband's genomic DNA as a template. The PCR primers included restriction enzyme sites for HindIII (P1: 5′AAaagcttGGTGCTGCAGGCAAA) and EcoRI (P2: 5′AAgaattcTTCTCTCCCAGAGGC). PCR products were then cloned into plasmid pcDNA3.0. Positive clones were sequenced to exclude the presence of additional variants and to distinguish between the wild-type or specific variants found in the proband. Transfection was performed using the LipoFiterTM 3.0 Liposomal Transfection Reagent (Hanbio) according to the manufacturer's instructions. Wild-type and mutant constructs were transiently transfected into HeLa cells, respectively, and pcDNA3.0 without inserts as a blank control. Total RNAs were isolated from transfected cells by the QIAzol Lysis Reagent (Qiagen) and reverse transcribed using a PrimeScript™ RT reagent Kit with gDNA Eraser (Takara). RT-PCR was performed using the P3 (5′-GGGCTTCCAGGCCTCCGTGGA) and P4 (5′-CTTCTCTGGCTTCTAGGG) located in exon 63 and exon 65 of COL7A1, respectively. RT-PCR products were separated by electrophoresis in a 2% agarose gel. The fragments were purified and inserted into a plasmid T-vector (Tsingke) according to the manufacturer's instructions for Sanger sequencing.

### 3 RESULTS

#### 3.1 Molecular findings

Two compound heterozygous variants in COL7A1 comprising c.3867delT in exon 31 and c.5532+5delAG in intron 64 were identified by CES and confirmed by Sanger sequencing (Figure 1b). Both variants are extremely rare and have not been reported in previous literature nor detected in the whole genome or exome sequencing public (1,000 genomes, gnomAD, and GO-ESP) and in-house databases. The c.3867delT, inherited from the father, is a deleterious variant leading to a frameshift and premature stop codon after 35 amino acids (p.G1290Efs*35). The c.5532+5delAG, inherited from the mother, is adjacent to the donor splicing site of intron 64, which was predicted to result in the disruption of a 5' donor splice site by the Human Splicing Finder (http://umd.be/HSF3/credits.html) (with a ΔCV score = −10.13).

#### 3.2 Splicing assays

Since the patient's RNA was not available, we performed an in vitro minigene assay to functionally validate the effect of c.5532+5delAG on splicing. RT-PCR analysis using the wild construct transinfected cells showed one amplicon. In contrast, the mutant construct showed an additional shorter amplicon, suggesting aberrant splicing (Figure 2b). To characterize the nucleotide change underlying this event, we further purified and sequenced the RT-PCR products. The results showed that the larger amplicon consisted of exon 63 (63 bp), 64 (45 bp), and 65 (36 bp), with a length of 144 bp, corresponding to the correctly spliced transcript. However, the shorter amplicon contained only exon 63 and 65, with a length of 99 bp (Figure 2c). This result indicated that the c.5532+5delAG variant resulted in the skipping of exon 64, leading to an in-frame deletion of 15 amino acids. Previous studies had demonstrated that the skipping of exon 64 was a causative variant (Horev et al., 2003; Huang, Wong, & Burd, 2011). Therefore, based on the splicing test and findings in other reports, c.5532+5delAG was classified as pathogenic.

#### 3.3 Prenatal diagnosis

Since pathogenicity of both variants validated in this family, amniocentesis and prenatal gene testing were performed at 19 weeks of another pregnancy. By targeted Sanger sequencing, neither of the two variants were found in the fetus (Figure 1b). Postnatal follow-up confirmed that the neonatal was unaffected with RDEB.

### 4 DISCUSSION

Dystrophic epidermolysis bullosa, featured with defective anchoring fibrils and consequent separation of the sub-basal lamina, is caused by variants in COL7A1 in either autosomal dominant or autosomal recessive fashion (Christiano et al., 1994; Fine et al., 2014). The diagnosis of DEB is based on clinical findings and the identification of causative variants in COL7A1. Genetic testing is necessary prenatally in families...
with affected members. The clinical phenotypes of DEB show considerable clinical variability and may overlap with other types of EB. Therefore, when molecular genetic testing is required, it is appropriate to apply more comprehensive genomic sequencing approaches (Gong, Liu, Li, & Xu, 2018; Has & Fischer, 2018; Lin et al., 2012; Mahajan et al., 2018).

The COL7A1 contains 118 exons, coding for the alpha-1 chain of type VII collagen composed of 2,944 amino acids. Type VII collagen functions as an anchoring fibril between the external epithelia and the underlying stroma. The protein consists of three distinctive structure domains: triple-helical collagenous (THC) domain encoded by exons 29–112, an amino terminus (NC-1) encoded by exons 2–28, carboxyl terminus (NC-2) encoded by exons 113–118 (Christiano et al., 1994; Lin et al., 2012).

In our patient, two compound heterozygous variants in COL7A1 were identified by CES and confirmed by Sanger sequencing. The paternal variant was a 1-bp deletion in exon 31 (c.3867delT), leading to a reading frameshift and premature termination codon (PTC) after 35 amino acids (p.G1290Efs*35). The consequence is the truncation of 1654 amino acids downstream exon 31, which include part of THC and complete NC-2. The maternal variant was a 2-bp deletion at position +4 and +5 in intron 64 (c.5532+4_5532+5delAG). As the reference sequence at the 5’ end of intron 64 is a typical donor splice site consensus sequence for U2 introns (GTRAGT), this variant was unsurprisingly predicted to damage the function of the 5’ donor splice site resulting aberrant splicing (Zhang, 1998). However, the definition of a noncanonical splicing variant, based on silico predictions alone, is not robust for clinical diagnoses. Since the patient’s RNA was not available, we conducted a minigene assay to clarify the effect of this change on splicing. The results indicated a complete in-frame skipping of exon 64 (15 amino acids) within the THC domain of the type VII collagen polypeptides. It was noteworthy that two variants of single nucleotide substitution at positions +4 (c.5532+4A>G) and +5 (c.5532+5G>A) in intron 64 of COL7A1 had been established as RDEB causative variants in two previous unrelated studies (Horev et al., 2003; Huang et al., 2011). One of the studies analyzed the specific outcome of both changes at the RNA and protein levels in a patient with c.5532+5G>A and another PTC variant in compound heterozygous status. The analysis of the patient’s RNA demonstrated that the c.5532+5G>A resulted in complete in-frame skipping of exon 64 within the THC region of the type VII collagen polypeptides. The protein analysis by immunofluorescence staining showed undetectable expression of type VII collagen polypeptides at the dermal–epidermal junction in the skin biopsy (Huang et al., 2011). Our research findings, together with previous reported experimental evidence, suggested that in-frame skipping of exon 64 is a loss of function mutation which will disrupt the production, secretion, and anchoring of the fibril assembly of type VII collagen.

Dystrophic epidermolysis bullosa has wide clinical spectrum but commonly severe. Although recent advances in therapeutics research, it is still incurable and profoundly affects functional abilities and quality of life till today. Early diagnosis is important to prevent and/or minimize tissue damage via appropriate treatment and management (El Hachem et al., 2014; Uitto, 2019; Uitto et al., 2018; Venti et al., 2020). On the other hand, due to concerns about the risk of recurrence, most of the patients families prefer to have healthy offspring through prenatal diagnosis or preimplantation diagnosis. Identification
of causative variant(s) of the proband is a prerequisite for prenatal diagnosis in families at risk for recurrence of EB. For ongoing risk pregnancies in which the molecular etiology of the proband is unclear, rapid gene diagnosis is vital and urgent. Our study demonstrated that exome sequencing is a rapid and efficient diagnostic strategy for DEB. In addition, we also demonstrated that the minigene assay was a reliable and easily applicable tool for evaluating the splicing effect of COL7A1 atypical splice variants.

ACKNOWLEDGMENT
The authors thank the patient and his family for their gracious contribution in this study.

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

AUTHOR’S CONTRIBUTION
Yongyi Ma collected the samples and designed the study. Neng Yang conducted the research, and analyzed the results. Neng Yang and Yongyi Ma wrote the paper. Hong Yao, Qing Chang, and Victor Zhang revised the paper. Zhiqing Liang and Xiongwei Cai initiated and organized the study.

DATA AVAILABILITY STATEMENT
Data sharing are not applicable to this article as no new data were created or analyzed in this study.

ORCID
Neng Yang https://orcid.org/0000-0002-0293-825X
Xiongwei Cai https://orcid.org/0000-0002-9990-2615

REFERENCES
Christiano, A. M., Hoffman, G. G., Chung-Honet, L. C., Lee, S., Cheng, W., Uitto, J., & Greenspan, D. S. (1994). Structural organization of the human type VII collagen gene (COL7A1), composed of more exons than any previously characterized gene. Genomics, 21(1), 169–179. https://doi.org/10.1006/geno.1994.1239

El Hachem, M., Zambruno, G., Bourdon-Lanoy, E., Ciasulli, A., Buisson, C., Hadj-Rabia, S., … Bodemer, C. (2014). Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa. Orphanet Journal of Rare Diseases, 9(1), 76. https://doi.org/10.1186/1750-1172-9-76

Fine, J.-D., Bruckner-Tuderman, L., Eady, R. A. J., Bauer, E. A., Bauer, J. W., Has, C., … Zambruno, G. (2014). Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification. Journal of the American Academy of Dermatology, 70(6), 1103–1126. https://doi.org/10.1016/j.jaad.2014.01.903

Gong, L., Liu, C. C., Li, Y. H., & Xu, X. G. (2018). Whole exome sequencing identified two point mutations of COL7A1 and FLG in a Chinese family with dystrophic epidermolysis bullosus pruriginosa and ichthyosis vulgaris. The Journal of Dermatology. https://doi.org/10.1111/exd.13668

Has, C., & Fischer, J. (2018). Inherited epidermolysis bullosa: New diagnostics and new clinical phenotypes. Experimental Dermatology, 28(10), 1146–1152. https://doi.org/10.1111/exd.13668

Horev, L., Waran Lalin, T., Martinez-Mir, A., Bagheri, B. A., Tadin-Strapps, M., Schneiderman, P. L., … Christiano, A. M. (2003). Identification of mutations in the COL7A1 gene in a proband with mild recessive dystrophic epidermolysis bullosa and aortic insufficiency. Clinical and Experimental Dermatology, 28(1), 80–84. https://doi.org/10.1046/j.1365-2230.2003.01190.x

Huang, L., Wong, Y., & Burd, A. (2011). A novel homozygous splice site mutation in COL7A1 in a Chinese patient with severe recessive dystrophic epidermolysis bullosa and squamous cell carcinoma. International Journal of Dermatology, 50(1), 52–56. https://doi.org/10.1111/j.1365-4632.2010.04642.x

Lin, Y., Chen, X.-J., Liu, W., Gong, B. O., Xie, J., Xiong, J.-H., … Yang, Z.-L. (2012). Two novel mutations on exon 8 and intron 65 of COL7A1 gene in two Chinese brothers result in recessive dystrophic epidermolysis bullosa. PLoS One, 7(11), e50579. https://doi.org/10.1371/journal.pone.0050579

Mahajan, R., Vellariikkal, S. K., Handa, S., Verma, A., Jayarajan, R., Kumar, A., … Scaria, V. (2018). Utility of whole-exome sequencing in detecting novel compound heterozygous mutations in COL7A1 among families with severe recessive dystrophic epidermolysis bullosa in India - Implications on diagnosis, prognosis and prenatal testing. Journal of the European Academy of Dermatology and Venereology, 32(12), e433–e435. https://doi.org/10.1111/jdv.14909

Uitto, J. (2019). Toward treatment and cure of epidermolysis bullosa. Proceedings of the National Academy of Sciences, 116(52), 26147–26149. https://doi.org/10.1073/pnas.1919347117

Uitto, J., Bruckner-Tuderman, L., McGrath, J. A., Riedl, R., & Robinson, C. (2018). EB2017-progress in epidermolysis bullosa research toward treatment and cure. The Journal of Investigative Dermatology, 138(5), 1010–1016. https://doi.org/10.1016/j.jid.2017.12.016

Vahidnezhad, H., Youssefian, L., Saedian, A. H., & Uitto, J. (2019). Phenotypic spectrum of epidermolysis bullosa: The paradigm of syndromic versus non-syndromic skin fragility disorders. The Journal of Investigative Dermatology, 139(3), 522–527. https://doi.org/10.1016/j.jid.2018.10.017

Venti, V., Scalia, B., Sauna, A., Nasca, M. R., Smilari, P., Praticò, A. D., … Pavone, P. (2020). Previously unreported COL7A1 mutation in a somali patient with dystrophic epidermolysis bullosa. Molecular Syndromology, 10(6), 332–338. https://doi.org/10.1159/000504210

Wagner, J. E., Ishida-Yamamoto, A., McGrath, J. A., Hordinsky, M., Keene, D. R., Woodley, D. T., … Tolar, J. (2010). Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. New England Journal of Medicine, 363(7), 629–639. https://doi.org/10.1056/NEJMoa1005011

Wang, Z., Lin, J., Qiao, K., Cai, S., Zhang, V. W., Zhao, C., & Lu, J. (2019). Novel mutations in HINT1 gene cause the autosomal recessive axonal neuropathy with neuromyotonia. European Journal of Medical Genetics, 62(3), 190–194. https://doi.org/10.1016/j.ejmg.2018.07.009

Zhang, M. Q. (1998). Statistical features of human exons and their flanking regions. Human Molecular Genetics, 7(5), 919–932. https://doi.org/10.1093/hmg/7.5.919

How to cite this article: Yang N, Ma Y-Y, Yao H, et al. Novel biallelic variants in COL7A1 cause recessive dystrophic epidermolysis bullosa. Mol Genet Genomic Med. 2020;8:e1347. https://doi.org/10.1002/mgg3.1347